Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of somatostatin analogues in hormone-refractory non-metastatic prostate cancer
2008-002338-31Phase 2Terminated
- Sponsor
- Hannover Medical School
- Start
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of lanreotide in prostate cancer (PCa) (2 arms), sponsored by Hannover Medical School. Primary endpoint: PSA response. Started Jul 2008; status: terminated.
02
Drugs
lanreotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-002338-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002338-31.